Devyser Diagnostics AB (Nasdaq: DVYSR) (STO:DVYSR), a provider of genetic test kits for laboratories, on Tuesday declared financial information for its full year from January to December 2022.
The company reported a loss after tax of SEK46.0m, compared to a loss of SEK20.7m in the previous year.
Earnings per share before and after dilution amounted to a loss of SEK2.89 in 2022, versus a loss of SEK1.85 in the year before.
Net sales increased by 35.4% to SEK126.6m, over SEK93.5 in 2021.
Devyser added that its board proposes no dividend for 2022.
Perrigo announces quarterly dividend
Valneva receives CEPI funding to boost access to world's first chikungunya vaccine
CVS Health announces quarterly dividend
Emmaus Life Sciences reports 2023 financial results
Quest Diagnostics to acquire LifeLabs from OMERS for USD1.35bn
Eli Lilly announces Q3 2024 dividend
Valneva's chikungunya vaccine IXCHIQ approved by Health Canada
AbbVie announces quarterly cash dividend
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline